Stevanato Group S.p.A. (STVN) AI Stock Analysis

Stevanato Group S.p.A. specializes in designing, manufacturing, and distributing a wide range of products and technologies tailored for the pharmaceutical and healthcare industries. Established in 1949 and based in Piombino Dese, Italy, the company is a subsidiary of Stevanato Holding S.R.L. Its integrated portfolio encompasses containment solutions, drug delivery systems, medical devices, diagnostic tools, analytical services, visual inspection machines, and assembling and packaging machines. Stevanato Group leverages advanced research and development alongside a global manufacturing footprint to ensure the integrity and stability of medications and vaccines for pharmaceutical partners worldwide.

Stevanato Group grew revenue from $843.9M in FY2021 to $1.14B in FY2025, recording a 5-year revenue CAGR of 11.5% from FY2020 to FY2025. Annual revenue growth moderated from 27.5% in FY2021 to 1.7% in FY2024 and 3.2% in FY2025. Gross margin stood at 29.0% in FY2025 compared to 31.4% in FY2021, while operating margin was 16.1% and net income reached $134.3M. In the latest quarter ended June 30, 2026, quarterly revenue increased 7.8% year-over-year, while quarterly earnings declined 26.5% year-over-year. TTM revenue reached $1.23B with a profit margin of 11.0%.

As of June 30, 2026, Stevanato Group held $83.6M in cash and short-term investments against $443.0M in total debt, resulting in net debt of $359.4M. Shareholders' equity was $1.55B, giving a debt-to-equity ratio of 0.29 and a current ratio of 1.61. In FY2025, operating cash flow reached $274.8M and free cash flow turned positive to $21.4M after three consecutive negative years. The company directed $253.3M toward capital expenditures and paid $14.2M in dividends in FY2025.

Stevanato Group trades at a trailing P/E of 33.2x and a forward P/E of 29.2x, both above the median of its US-listed Healthcare peers at 24.6x and 17.3x, respectively. Its enterprise value of $6.34B yields an EV/EBITDA of 18.9x, compared to the peer median of 12.0x, while its price-to-sales ratio is 4.2x against the peer median of 4.1x. Over the past year, the stock fell 21.3%, underperforming the SPY gain of 16.8%. Over a 5-year span, STVN dropped 21.1% while SPY advanced 83.0%.

Stevanato Group pays an annual dividend with a forward rate of $0.06 per share, yielding 0.33% at the last close of $18.90. The payout ratio is 9.4%, and the company has paid dividends for 5 consecutive years. Its last ex-dividend date was June 11, 2026.

Wall Street coverage includes 7 Strong Buy, 2 Buy, and 5 Hold ratings, with no Sell or Strong Sell recommendations. The mean price target of $24.47 stands 29.5% above the last close of $18.90. For the fiscal year ending December 31, 2026, analysts estimate EPS of $0.70 on revenue of $1.27B. For the following fiscal year, 14 analysts project EPS of $0.83 on revenue of $1.38B. Stevanato Group beat EPS estimates in all of the last 4 quarters, and its next earnings date is November 5, 2026.

This page is an AI-written research summary of Stevanato Group S.p.A. (STVN). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: STVN income statement, STVN balance sheet, STVN key metrics, STVN analyst forecast, STVN chart. See the STVN stock overview for the latest quote and news.